Edwards Lifesciences
Edwards Lifesciences is a global leader in structural heart innovation, specializing in the development of medical technologies for heart valve disease and critical care monitoring. The company focuses on transformative product innovation and high-quality clinical evidence to provide both surgical and transcatheter therapies for aortic, mitral, tricuspid, and pulmonic heart valves.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Transcatheter Aortic Valve Replacement (TAVR)
primaryTechnologies designed for the replacement of heart valves via catheter-based approaches, eliminating the need for traditional open-heart surgery.
SAPIEN, SAPIEN XT, SAPIEN 3, SAPIEN 3 Ultra
Interventional Cardiologists, Cardiac Surgeons, Hospitals
Surgical Structural Heart
majorTraditional surgical tissue heart valves and repair therapies used by surgeons during open-heart procedures to treat diseased or damaged valves.
INSPIRIS RESILIA, EDWARDS INTUITY Elite, Carpentier-Edwards Physio
Cardiac Surgeons, General Hospitals
Transcatheter Mitral and Tricuspid Therapies (TMTT)
moderateA portfolio of transcatheter repair and replacement technologies specifically for patients suffering from mitral and tricuspid valve diseases.
PASCAL, EVOQUE
Interventional Cardiologists, Cardiac Surgeons, Specialized Heart Centers
Critical Care
moderateAdvanced hemodynamic monitoring systems used in surgical and intensive care settings to measure a patient's heart function and fluid status.
FloTrac, ClearSight, ForeSight, HemoSphere
Anesthesiologists, Intensivists, Critical Care Units
Segment Financials
Transcatheter Aortic Valve Replacement — Net Sales
View metricTranscatheter Mitral and Tricuspid Therapies — Net Sales
View metricSurgical — Net Sales
View metricUnited States — Cost of Sales
View metricEurope — Cost of Sales
View metricBusiness Overview
Competitive Position
Edwards is the global market leader in transcatheter aortic valve replacement and a pioneer in surgical tissue heart valves.
Geographies
United States, Europe, Japan, Rest of World
Customer Segments
Hospitals, Specialized Medical Clinics, Healthcare Systems
Upstream Dependencies
Bovine and porcine tissue suppliers, Specialized medical-grade polymers and metals, Electronic component manufacturers for monitoring consoles
Downstream Customers
Acute care hospitals, Cardiac catheterization laboratories, Government healthcare providers, Private insurance payers
Competitors & Partners
Edwards Lifesciences FAQ
Common questions about Edwards Lifesciences
Edwards Lifesciences is a global leader in structural heart innovation, specializing in the development of medical technologies for heart valve disease and critical care monitoring. The company focuses on transformative product innovation and high-quality clinical evidence to provide both surgical and transcatheter therapies for aortic, mitral, tricuspid, and pulmonic heart valves.
Edwards Lifesciences (EW) has a market capitalization of $46.9B and trades on NYSE.
Edwards Lifesciences generated $6.3B in trailing twelve-month revenue with net income of $1.1B, representing a net margin of 17.4%. Gross margin stands at 77.9%, with free cash flow of $1.1B. These figures are based on the Q1 2026 filing.
Edwards Lifesciences's key competitors include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Edwards Lifesciences has approximately 19,800 employees.